. . . "For use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients."@en . . . . . . . . . . . . . . . . . . . . . . "Guanfacinum"@en . "investigational"@en . . . . . . "In individuals with normal renal function, guanfacine and its metabolites are excreted primarily in the urine."@en . . . . . "Guanfacina"@en . . . "Estulic"@en . . "approved"@en . . . "Guanfacine"@en . " "@en . . . . . . "U.S. Patent 3,632,645."@en . "Guanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic vasomotor centers, which contributes predominantly to the hypotensive effects of the drug. Central effects of guanfacine lead to reduced peripheral sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. The stimulation of peripheral alpha(2)-adrenergic receptors may also contribute to hypotensive effects. "@en . . . " "@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "* 6.3 L/kg"@en . . . . . . "Approximately 70% bound to plasma proteins, independent of drug concentration."@en . "Rapid and complete, with an oral bioavailability of approximately 80%."@en . . . . . . "Symptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD₅₀=165mg/kg (orally in mice)"@en . . . . . . . "A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]"@en . "29110-47-2"@en . "17 hours (range 10-30 hours)"@en . . . . . "Humans and other mammals"@en .